Delivery Order SPE2DB22D3011-SPE2DB25FP8UW

Award Date 1/21/25
Potential Completion Date 1/22/25
Potential Value $23K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is for the supply of XIFAXAN 550 mg tablets to the Defense Logistics Agency (DLA). The contract is a Delivery Order with a Firm Fixed Price of $30,902.72 and an ultimate completion date of July 17, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical...
This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, is for the delivery of XIFAXAN 550 mg tablets to the U.S. Department of Defense's Medical Supply Chain. The single-award, firm-fixed-price, indefinite delivery contract (IDC) has a potential value of $999,999,999.00 and a performance period through December 31, 2025. This IDC serves as the primary contract vehicle for Amerisourcebergen to provide pharmaceutical products and medical supplies...
This contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is a Delivery Order against the Defense Logistics Agency (DLA) Troop Support Medical Indefinite Delivery Contract (IDC) valued at $999,999,999. The award, valued at $11,837.36, is for the delivery of XIFAXAN 550 MG tablets to support federal healthcare programs. The contract has a period of performance through October 2024 and does not have a set-aside designation, indicating open competition. As a critical...
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA) Troop Support Medical. The contract, with a ceiling value of $24,162.73, is a Delivery Order under the company's $999,999,999 Indefinite Delivery Contract (IDC) with the DLA that runs through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to provide a comprehensive range of pharmaceutical products...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, was issued by the Defense Logistics Agency (DLA) in the amount of $14,281.20. The award is a Firm Fixed Price Delivery Order for 4566957049 - XIFAXAN 550 MG TABLET 60S, a prescription medication. The contract has an ultimate completion date of January 17, 2025. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 through...
The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical distribution company Amerisourcebergen Corporation. The contract, valued at $2,040.98, is for the delivery of XIFAXAN 550 mg tablets to support military treatment programs and facilities. This delivery order falls under a larger indefinite delivery contract (IDC) awarded by DLA to Amerisourcebergen Drug Corp, with a potential value of...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, one of the largest pharmaceutical distribution companies in the world. The $9,452.75 fixed-price delivery order is for the supply of XIFAXAN 550 mg tablets to support the Department of Defense's medical treatment programs and facilities globally. Amerisourcebergen holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop...
This federal contract award, valued at $8,914.07, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation. The contract is for the delivery of XIFAXAN 550 MG TABLET 60S, a pharmaceutical product, to DLA facilities supporting the Department of Defense worldwide. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued up to $999,999,999.00 through December 31, 2025. This...
This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $10,747.00 firm fixed-price delivery order is for the supply of XIFAXAN 550 MG TABLET 60S, a pharmaceutical product. The contract has an ultimate completion date of February 14, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $10,542.97 firm fixed-price delivery order is for XIFAXAN 550 MG TABLET 60S, a prescription medication. The contract has an ultimate completion date of March 19, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for...
  • SPE2DB22D3011
    Indefinite Delivery Contract
  • SPE2DB22D3011-SPE2DB25FP8UW
    Delivery Order

This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is for the delivery of XIFAXAN 550 mg tablets to the Defense Logistics Agency (DLA). The contract has a ceiling value of $23,242.88 and runs through January 2025. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at $999,999,999, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition. In addition to the DLA contract, Amerisourcebergen also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, which covers similar medical products and prescription drugs.

Generated 5/21/25, 10:21 AM